Highest-materiality recent filing
Marpai extends CEO-held promissory notes totaling $660k to Sept 2026
Amended two notes issued to CEO Damien Lamendola: $410k (Feb 2026) and $250k (Mar 2026).
Marpai issues $250K promissory note to CEO at 12% for working capital
Principal $250,000; interest 12% per annum; payable May 10, 2026.
Marpai issues $410K promissory note to CEO Lamendola at 12%, due April 11, 2026
Principal $410,000; interest 12% per annum; maturity April 11, 2026.
Marpai President resigns; CEO Damien Lamendola appointed as President
Dallas Scrip resigned as President of Marpai effective Jan 30, 2026, with no disagreement with the Company.
Marpai raises ~$350K via private placement of 350K shares and warrants
Issued 350,000 shares of Class A common stock and warrants to purchase up to 700,000 shares at $1.00/unit.
Marpai raises ~$4M via private placement of common stock and warrants
Issued 3.85M shares at $1.00 per share plus warrants for 7.7M shares at $1.00, exercisable for 3 years.
Marpai Q3 operating expenses down 24% YoY to $3.8M; net loss narrows to $3.5M
Operating expenses decreased 24% YoY from $5.0M to $3.8M for Q3 2025.
Marpai amends charter to authorize 2M blank-check preferred shares
Certificate of Amendment filed Oct 17, 2025 authorizes 2,000,000 shares of blank-check preferred stock.
Marpai issues 147,058 shares at $1.36 to CEO-controlled fund in private placement
Sold 147,058 Class A common shares at $1.36 each to HillCour Investment Fund, LLC, controlled by CEO Damien Lamendola.
Marpai raises ~$1.1M in private placement; CEO's entity buys 86% of shares
Issued 1,038,519 shares at $1.0592/share in unregistered private placement to three investors.
Marpai President John Powers resigns; COO Dallas Scrip appointed as successor
John Powers resigned as President effective Aug 29, 2025, due to personal health; will serve as part-time Senior Consultant.
Marpai shareholders elect 6 directors, ratify UHY, approve blank-check preferred amendment
All six director nominees elected: Lamendola (10,978,996 for), Eitan (10,979,296), Shiv (10,932,384), DiClaudio (10,562,391), Calabrese (10,982,991), Pons (10,983,116).
Marpai Q2 2025: net loss cut 66% to $4.4M; op ex down 70%; CEO targets Q1 2026 profitability
Operating expenses fell 70% ($9.9M savings) to $3.6M; operating loss reduced 71% to $3.6M.
Marpai raises ~$650k in private placement; CEO entity buys 371k shares
Sold 603,640 shares of Class A common stock at $1.0768/share for aggregate proceeds of ~$650,000.
Marpai raises ~$150K in private placement; CEO-affiliated entity buys 86,805 shares at $1.152
Issued 130,208 shares of Class A common stock at $1.152 per share, raising aggregate proceeds of approximately $150,000.
Marpai Q1 2025 revenue $5.4M down 27% YoY; operating loss narrows 45% to $2.3M
Net revenue $5.4M, down $2.0M (27%) vs Q1 2024; operating expenses cut 33% to $7.7M.
Marpai appoints Dallas Scrip as COO effective June 2, 2025
Dallas Scrip appointed COO and President of MarpaiRx, effective June 2, 2025.
Marpai Q4 net loss improves 67.5% YoY; full-year adjusted EBITDA loss narrows to $9.1M
Q4 net revenue $6.6M, down 6% sequentially; operating loss $2.7M, improved 12.2% from Q3.
Marpai reduces Base Purchase amounts by $3M with AXA; new payment schedule through 2027
Reduction criteria met as of Dec 31, 2024: largest shareholder contributed ≥$3M, listing maintained, timely payments.
Marpai secures $5M additional non-dilutive debt financing from JGB
Additional $5M financing from JGB Collateral LLC via senior secured debentures (principal $5.376M).
Marpai prices $702k private placement of 621,194 shares at $1.13 each
Gross proceeds of $701,950 from sale of 621,194 Class A common shares at $1.13/share.
Marpai reports Q3 2024 net loss of $3.6M, revenue down 20% YoY
Net revenue $7.0M, down 20% YoY from $8.7M in Q3 2023.
Marpai raises ~$1.3M via private placement of 2.7M shares at $0.481; CEO affiliate participates
Issued 2,702,702 shares at $0.481 per share, raising approximately $1.3 million.
Marpai Q2 net loss widens to $13M on $7.6M goodwill impairment; revenue drops 28%
Net revenues $7.2M, down 28% YoY from $10.1M in Q2 2023.
Marpai redeems $5M of convertible debentures, reducing outstanding to $6.83M
Effective June 21, 2024, Marpai redeemed $5M principal of Senior Secured Convertible Debentures under optional provision.
Marpai withdraws from Nasdaq hearings, expects delisting on May 29; trading to move to OTCQX
Marpai was not compliant with Nasdaq minimum stockholders' equity requirement under Rule 5550(b)(1).
Director Mike Dendy resigns from Marpai board effective May 12, 2024
Director Mike Dendy resigned from the Board effective May 12, 2024.
Marpai Q1 2024 net revenues $7.4M (-24% YoY); net loss improves 51% to $4.3M
Net revenues $7.4M, down 24% YoY; gross profit $2.5M (-23% YoY).
Marpai shareholders approve 2024 equity plan and blank-check preferred stock at annual meeting
Stockholders approved 2024 Global Stock Incentive Plan with 4,604,962 for, 200,399 against.
Marpai issues $11.83M convertible debentures; net proceeds $11M; conversion $3.00/share
Aggregate principal $11.83M; purchase price $11M; OID of $830,000.
Marpai Q4 2023 net revenues $8.7M up 14% YoY; net loss improved to $5.0M
Q4 net revenues $8.7M, up 14% YoY; gross profit $3.0M, up 6.5%.
Nasdaq panel grants Marpai extension to May 28 to meet $35M MVLS listing requirement
Nasdaq Hearings Panel granted extension until May 28, 2024 to regain compliance with MVLS minimum of $35M.
Marpai issues 910k shares at $1.65 to CEO-affiliated fund in private placement
Sold 910,000 Class A common shares to HillCour Investment Fund LLC (CEO Damien Lamendola controls) at $1.65/share.
Marpai reports preliminary Q4 revenue up 14% YoY, operating loss improves $5M
Q4 2023 net revenue ~$8.7M (+14% YoY); FY2023 ~$37.2M (+53% YoY).
Marpai reports preliminary Q4 2023 revenue $8.7M (+14% YoY), operating loss improves $5M
Q4 2023 net revenues ~$8.7M, up ~14% from Q4 2022; FY 2023 net revenues ~$37.2M, up ~53% YoY.
Marpai signs three-year off-cycle TPA agreement for at least 20,000 households
Three-year healthcare benefit services contract with a regional southeast organization.
On May 13, 2025, the Board of Directors of Marpai, Inc. (the “Company”) appointed Dallas Scrip, age 42, as Chief Operating Officer of the Company, effective as of June 2, 2025.
On May 12, 2024, Mike Dendy notified the board of directors (the “Board”) of Marpai, Inc. (the “Company”) of his resignation from the Board, effective immediately.
Max materiality 0.80 · Median 0.57 · Most common event other_material